144 citations
,
November 2020 in “Frontiers in immunology” This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.
April 2018 in “Journal of Investigative Dermatology” In this study, researchers reported that IL-17C plays a key pro-inflammatory role in human skin diseases and may be a promising therapeutic target for inflammatory skin conditions.
August 2026 in “eScholarship (California Digital Library)” This study explored IL-17D's role in skin biology and found no significant difference in disease progression between IL-17D KO and WT mice in skin inflammation models, but IL-17D did promote cell migration and modestly accelerated wound healing, suggesting it may influence tissue repair processes.
July 2026 in “Dermatology Practical & Conceptual” This narrative review reports that IL-17 and IL-23 inhibitors, while effective for psoriasis and other inflammatory diseases, can cause a variety of skin reactions that resemble primary dermatoses, highlighting the need for careful diagnosis and varied management strategies.
49 citations
,
August 2022 in “Frontiers in Immunology” This paper discusses the evolving understanding of psoriasis pathogenesis with no new clinical findings; the authors highlight the role of T-cell plasticity and regulatory cells, calling for further clinical applications using single-cell technologies.